<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04778397</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-546-5857</org_study_id>
    <secondary_id>2020-003949-11</secondary_id>
    <nct_id>NCT04778397</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety and Efficacy of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Previously Untreated Adults With TP53 Mutant Acute Myeloid Leukemia</brief_title>
  <acronym>ENHANCE-2</acronym>
  <official_title>A Phase 3, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Previously Untreated Patients With TP53 Mutant Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to compare the efficacy of magrolimab + azacitidine&#xD;
      versus venetoclax + azacitidine in adults with previously untreated TP53 mutant acute myeloid&#xD;
      leukemia (AML) who are appropriate for non-intensive therapy as measured by overall survival&#xD;
      (OS).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2021</start_date>
  <completion_date type="Anticipated">November 2024</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival (OS) in Participants Appropriate for Non-intensive Therapy</measure>
    <time_frame>Randomization up to death or end of study (up to 27 months) whichever occurs first</time_frame>
    <description>The OS is measured from the date of randomization to the date of death from any cause. Those whose deaths are not observed during the study will be censored at their last known alive date.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival in All Participants</measure>
    <time_frame>Randomization up to death or end of study (up to 27 months) whichever occurs first</time_frame>
    <description>The OS is measured from the date of randomization to the date of death from any cause. Those whose deaths are not observed during the study will be censored at their last known alive date.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-Free Survival (EFS) in All Participants</measure>
    <time_frame>Randomization up to end of study (up to 27 months)</time_frame>
    <description>The EFS is defined as time from the date of randomization to the earliest date of documented relapse from complete remission (CR), treatment failure (defined as failure to achieve CR within 6 months of treatment with magrolimab + azacitidine or venetoclax + azacitidine, or up to 2 months of treatment with 7 + 3 chemotherapy), or death from any cause. Those who are not observed to have one of these events during the study will be censored at the date of their last response assessment with clear documentation of no relapse during the study. The date of randomization will be assigned as the event date for participants with treatment failure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Red Blood Cell (RBC) Transfusion Independence Conversion Rate in All Participants</measure>
    <time_frame>First dose date up to last dose date (Maximum: 24 months)</time_frame>
    <description>The RBC transfusion independence conversion rate is the percentage of participants who have a 56-day or longer period with no RBC transfusions at any time between the date of first dose of study treatment and discontinuation of study treatment among all participants who are RBC transfusion dependent at baseline. The RBC transfusion dependence at baseline is defined as having received an RBC or whole blood transfusion within the 28 days prior to the first dose of study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet Transfusion Independence Conversion Rate in All Participants</measure>
    <time_frame>First dose date up to last dose date (Maximum: 24 months)</time_frame>
    <description>The platelet transfusion independence conversion rate is the percentage of participants who have a 56 day or longer period with no platelet transfusions at any time between the date of first dose of study treatment and discontinuation of study treatment among all participants who are platelet transfusion dependent at baseline. Platelet transfusion dependence at baseline is defined as having received a platelet transfusion within the 28 days prior to the first dose of study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Complete Remission (CR) in All Participants</measure>
    <time_frame>6 months for the Magrolimab + Azacitidine; Control Arm: Venetoclax + Azacitidine arm, and 2 months for Control Arm: 7+3 Chemotherapy</time_frame>
    <description>The rate of CR is the percentage of participants who achieve a CR, including complete remission without minimal residual disease (CR MRD-) and complete remission with positive or unknown minimal residual disease (CR MRD+/unk) as defined by investigators based on European Leukemia Net 2017 recommendations for AML (ELN 2017 AML) with modifications, while on study prior to initiation of any new anti-AML therapy or stem cell transplant (SCT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of CR Without Minimal Residual Disease (CR MRD-) in All Participants</measure>
    <time_frame>6 months for the Magrolimab + Azacitidine; Control Arm: Venetoclax + Azacitidine arm, and 2 months for Control Arm: 7+3 Chemotherapy</time_frame>
    <description>The rate of CR MRD- is the percentage of participants who achieve a CR MRD- as defined by investigators based on ELN 2017 AML with modifications, while on study prior to initiation of any new anti-AML therapy or SCT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time Until Meaningful Definitive Deterioration (TUDD) on the EORTC QLQ-C30 GHS/QoL Scale in All Participants</measure>
    <time_frame>Day 1 of each cycle (up to 24 months); Cycle=28 days</time_frame>
    <description>TUDD on European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core Questionnaire (EORTC QLQ-C30) Global Health Status/Quality of Life (GHS/QoL) scale is defined as time from randomization date to earlier date that score is consistently at least 10 points worse than baseline score/death. Questionnaire includes 30 questions resulting in 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, social functioning), 1 GHS/QoL scale, 3 symptom scales (fatigue, nausea and vomiting, pain), and 6 single items (dyspnea, insomnia, loss of appetite, constipation, diarrhea, financial difficulties). After linear transformation, all scales and single item measures range in score from 0-100. Higher score on GHS/QoL scale means better GHS/QoL. Those whose score does not reach meaningful definitive deterioration and whose deaths are not observed during study will be censored at their last GHS/QoL scale assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TUDD on the EORTC QLQ-C30 Physical Functioning Scale in All Participants</measure>
    <time_frame>Day 1 of each cycle (up to 24 months); Cycle=28 days</time_frame>
    <description>TUDD on the EORTC QLQ C30 physical functioning scale is defined as time from the date of randomization to the earlier date that the score is consistently at least 10 points worse than the baseline score or death. Physical functioning scale is one of the five functional scales of the EORTC QLQ C30 questionnaire. After linear transformation, scale range in score from 0-100. A higher score on functional scales means better functioning and better quality of life. Those whose score does not reach meaningful definitive deterioration and whose deaths are not observed during the study will be censored at their last physical functioning scale assessment date.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of CR and Complete Remission with Partial Hematologic Recovery (CR+CRh) in All Participants</measure>
    <time_frame>6 months for the Magrolimab + Azacitidine; Control Arm: Venetoclax + Azacitidine arm, and 2 months for Control Arm: 7+3 Chemotherapy</time_frame>
    <description>The CR+CRh rate is the percentage of participants who achieve a CR (including CR MRD- and CR MRD+/unk) or CRh as defined by CR with partial platelet and absolute neutrophil count (ANC) recovery while on study prior to initiation of any new anti-AML therapy or SCT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Complete Remission (DCR)</measure>
    <time_frame>First CR achieved within 6 months for the Magrolimab + Azacitidine; Control Arm: Venetoclax + Azacitidine arm, and 2 months for Control Arm: 7+3 Chemotherapy up to the end of study (up to 27 months)</time_frame>
    <description>The DCR is measured from the time the assessment criteria are first met for CR (including CR MRD- and CR MRD+/unk) until the first date of AML relapse or death (including assessments post SCT). Those who are not observed to have relapsed disease or death while on study will be censored at the date of their last response assessment with no evidence of relapse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of CR+CRh</measure>
    <time_frame>First CR or CRh achieved within 6 months for the Magrolimab + Azacitidine; Control Arm: Venetoclax + Azacitidine arm, and 2 months for Control Arm: 7+3 Chemotherapy up to the end of study (up to 27 months)</time_frame>
    <description>The duration of CR+CRh is measured from the time the assessment criteria are first met for CR (including CR MRD- and CR MRD+/unk) or CRh until the first date of AML relapse or death (including assessments post SCT). Those who are not observed to have relapsed disease or death while on study will be censored at the date of their last response assessment with no evidence of relapse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Experiencing Grade ≥ 3 Treatment-Emergent Adverse Events (TEAEs) According to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0</measure>
    <time_frame>First dose date up to last dose date (Maximum: 24 months) plus 70 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Experiencing Grade ≥ 3 Treatment-Emergent Laboratory Abnormalities According to the NCI CTCAE Version 5.0</measure>
    <time_frame>First dose date up to last dose date (Maximum: 24 months) plus 70 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Concentration of Magrolimab</measure>
    <time_frame>Within 72 hours predose on Day 1 of Cycle 1, within 12 hours predose on Day 8 of Cycle 1 and Day 1 of Cycles 2, 3, 5, 7, 10, 13, and end of treatment (EOT) EOT=Maximum: 24 months (Cycle=28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Anti-Magrolimab Antibody Incidence</measure>
    <time_frame>Within 72 hours predose on Day 1 of Cycle 1, within 12 hours predose on Day 1 of Cycles 2, 3, 5, 7, 10, 13 and end of treatment (EOT) EOT=Maximum: 24 months (Cycle=28 days)</time_frame>
    <description>Rate of anti-magrolimab antibody incidence is defined as the percentage of participants with anti-magrolimab antibodies.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">346</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Magrolimab + Azacitidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive an escalating dose of magrolimab and a fixed dose of azacitidine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Arm: Venetoclax + Azacitidine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants who are appropriate for non-intensive therapy will receive an escalating dose of venetoclax and a fixed dose of azacitidine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Arm: 7+3 Chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants who are appropriate for intensive therapy will receive 7+3 chemotherapy: 7 day treatment with cytarabine and 3 day treatment with daunorubicin or idarubicin during induction and high-dose cytarabine and steroidal eye drops during consolidation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Magrolimab</intervention_name>
    <description>Administered intravenously (IV).</description>
    <arm_group_label>Magrolimab + Azacitidine</arm_group_label>
    <other_name>GS-4721</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venetoclax</intervention_name>
    <description>Administered orally at a dose of 100 milligrams (mg) on Day 1, 200 mg on Day 2, 400 mg on Days 3-28 during Cycle 1, followed by 400 mg on Days 1-28 during every cycle (Cycle=28 days).</description>
    <arm_group_label>Control Arm: Venetoclax + Azacitidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azacitidine</intervention_name>
    <description>Administered either subcutaneously (SC) or IV, 75 milligrams per square meter (mg/m^2) on Days 1-7 or Days 1-5, 8 and 9 during every cycle (Cycle=28 days).</description>
    <arm_group_label>Control Arm: Venetoclax + Azacitidine</arm_group_label>
    <arm_group_label>Magrolimab + Azacitidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Induction: administered continuous infusion, 100 or 200 mg/m^2 on Days 1-7 (7+3 induction) and if needed Days 1-5 (5+2 induction) during a cycle (Cycle=Up to 42 Days).&#xD;
Consolidation: administered IV, 3000 mg/m^2 on Days 1, 3, and 5 once every 12 hours for up to 4 cycles.</description>
    <arm_group_label>Control Arm: 7+3 Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daunorubicin</intervention_name>
    <description>Administered IV peripherally (IVP), 60 mg/m^2 on Days 1-3 (7+3 induction) and if needed Days 1-2 (5+2 induction) during a cycle (Cycle=Up to 42 days).</description>
    <arm_group_label>Control Arm: 7+3 Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Idarubicin</intervention_name>
    <description>Administered IV, 12 mg/m^2 on Days 1-3 (7+3 induction) and if needed Days 1-2 (5+2 induction) during a cycle (Cycle=Up to 42 days).</description>
    <arm_group_label>Control Arm: 7+3 Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Steroidal Eye Drops</intervention_name>
    <description>Administered per institutional standard during consolidation.</description>
    <arm_group_label>Control Arm: 7+3 Chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Individuals with histological confirmation of AML by World Health Organization&#xD;
             criteria, previously untreated for AML, and who have presence of at least 1 TP53 gene&#xD;
             mutation that is not benign or likely benign based on evaluation by central laboratory&#xD;
             (individuals with biallelic 17p deletions, loss of both 17p alleles, are eligible&#xD;
             based on locally evaluated cytogenetics/karyotype/fluorescence in situ hybridization&#xD;
             (FISH) report)&#xD;
&#xD;
          -  Individuals with white blood cell (WBC) count ≤ 20×10^3/microliter (μL) prior to&#xD;
             randomization. If the individual's WBC is &gt; 20×10^3/μL prior to randomization, the&#xD;
             individual can be enrolled, assuming all other eligibility criteria are met. However,&#xD;
             the WBC should be ≤ 20×10^3/μL prior to the first dose of study treatment and prior to&#xD;
             each magrolimab dose for Cycle 1 (if the individual is randomized to the experimental&#xD;
             arm) Note: Individuals can be treated with hydroxyurea throughout the study or prior&#xD;
             to randomization to reduce the WBC to ≤ 20×10^3/μL to enable eligibility for study&#xD;
             drug dosing. Oral etoposide (up to 200 mg orally per day) may be given as an&#xD;
             alternative to hydroxyurea for individuals who are intolerant to hydroxyurea or cannot&#xD;
             achieve sufficient WBC lowering on hydroxyurea.&#xD;
&#xD;
          -  The hemoglobin must be ≥ 9.5 grams per deciliter (g/dL) prior to initial dose of study&#xD;
             treatment for individuals with prior cardiac history (eg, ischemic heart disease, left&#xD;
             ventricular ejection fraction (LVEF) ≤ 45%, symptomatic congestive heart failure, or&#xD;
             other conditions that may be sensitive to demand ischemia). Transfusions are allowed&#xD;
             to meet hemoglobin eligibility&#xD;
&#xD;
          -  Individual has provided informed consent&#xD;
&#xD;
          -  Individual is willing and able to comply with clinic visits and procedure outlined in&#xD;
             the study protocol&#xD;
&#xD;
          -  Individuals must have an Eastern Cooperative Oncology Group (ECOG) performance status&#xD;
             of 0 to 2, except for individuals less than 75 years of age and appropriate for&#xD;
             non-intensive treatment. For these individuals, the ECOG performance status score may&#xD;
             be 0 to 3&#xD;
&#xD;
          -  Individuals must have adequate renal function as demonstrated by a creatinine&#xD;
             clearance ≥ 30 milliliters per minute per 1.73 square meter (mL/min/1.73m^2);&#xD;
             calculated by the Cockcroft Gault formula or measured by 24 hours urine collection&#xD;
&#xD;
          -  Adequate cardiac function as demonstrated by:&#xD;
&#xD;
               -  Lack of symptomatic congestive heart failure and clinically significant cardiac&#xD;
                  arrhythmias and ischemic heart disease&#xD;
&#xD;
               -  LVEF &gt; 50% for individuals appropriate for intensive therapy&#xD;
&#xD;
          -  Adequate liver function as demonstrated by:&#xD;
&#xD;
               -  Aspartate aminotransferase ≤ 3.0 × upper limit of normal (ULN)&#xD;
&#xD;
               -  Alanine aminotransferase ≤ 3.0 × ULN&#xD;
&#xD;
               -  Total bilirubin ≤ 1.5 × ULN, or primary unconjugated bilirubin ≤ 3.0 × ULN if&#xD;
                  individual has a documented history of Gilbert's syndrome or genetic equivalent&#xD;
&#xD;
          -  Pretreatment blood cross-match completed&#xD;
&#xD;
          -  Males and females of childbearing potential who engage in heterosexual intercourse&#xD;
             must agree to use protocol-specified method(s) of contraception&#xD;
&#xD;
          -  Individuals must be willing to consent to mandatory pretreatment and on-treatment bone&#xD;
             marrow biopsies (aspirate and trephines).&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Positive serum pregnancy test&#xD;
&#xD;
          -  Breastfeeding female&#xD;
&#xD;
          -  Known hypersensitivity to any of the study drugs, the metabolites, or formulation&#xD;
             excipient&#xD;
&#xD;
          -  Prior treatment with any of the following:&#xD;
&#xD;
               -  Cluster of differentiation 47 (CD47) or signal regulatory protein alpha&#xD;
                  (SIRPα)-targeting agents&#xD;
&#xD;
               -  Antileukemic therapy for the treatment of AML (excluding hydroxyurea or oral&#xD;
                  etoposide), hypomethylating agent (HMA), low dose cytarabine and/or venetoclax&#xD;
                  Note: Individuals with prior myelodysplastic syndrome (MDS) who have not received&#xD;
                  prior HMAs or chemotherapeutic agents for MDS are allowed on study. Other prior&#xD;
                  MDS therapies including, but not limited to, lenalidomide, erythroid stimulating&#xD;
                  agents, or similar RBC-direct therapies, are allowed. Localized non-central&#xD;
                  nervous system (CNS) radiotherapy, erythroid and/or myeloid growth factors,&#xD;
                  hormonal therapy with luteinizing hormone-releasing hormone agonists for prostate&#xD;
                  cancer, hormonal therapy or maintenance for breast cancer, and treatment with&#xD;
                  bisphosphonates and receptor activator of nuclear factor kappa-B ligand&#xD;
                  inhibitors are also not criteria for exclusion.&#xD;
&#xD;
          -  Current participation in another interventional clinical study&#xD;
&#xD;
          -  Known inherited or acquired bleeding disorders&#xD;
&#xD;
          -  Individuals appropriate for non-intensive therapy, who have received treatment with&#xD;
             strong and/or moderate cytochrome P450 enzyme 3A (CYP3A) inducers within 7 days prior&#xD;
             to the initiation of study treatments&#xD;
&#xD;
          -  Individuals appropriate for non-intensive therapy who have consumed grapefruit,&#xD;
             grapefruit products, Seville oranges (including marmalade containing Seville oranges)&#xD;
             or starfruit within 3 days prior to the initiation of study treatment&#xD;
&#xD;
          -  Individuals appropriate for non-intensive therapy who have malabsorption syndrome or&#xD;
             other conditions that preclude enteral route of administration&#xD;
&#xD;
          -  Clinical suspicion of active CNS involvement with AML&#xD;
&#xD;
          -  Individuals who have acute promyelocytic leukemia&#xD;
&#xD;
          -  Significant disease or medical conditions, as assessed by the Investigator and&#xD;
             Sponsor, that would substantially increase the risk-benefit ratio of participating in&#xD;
             the study. This includes, but is not limited to, acute myocardial infarction within&#xD;
             the last 6 months, unstable angina, uncontrolled diabetes mellitus, significant active&#xD;
             infections, and congestive heart failure New York Heart Association Class III-IV&#xD;
&#xD;
          -  Second malignancy, except neoplasms such as MDS/myeloproliferative disorders that can&#xD;
             transform to AML, or treated basal cell or localized squamous skin carcinomas,&#xD;
             localized prostate cancer, or other malignancies for which individuals are not on&#xD;
             active anti-cancer therapies and have had no evidence of active malignancy for at&#xD;
             least ≥ 1 year Note: Individuals on maintenance therapy alone who have no evidence of&#xD;
             active malignancy for at least ≥ 1 year are eligible.&#xD;
&#xD;
          -  Known active or chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infection&#xD;
             or human immunodeficiency virus (HIV) infection in medical history&#xD;
&#xD;
          -  Active HBV, and/or active HCV, and/or HIV following testing at screening:&#xD;
&#xD;
               -  Individuals who test positive for hepatitis B surface antigen (HBsAg).&#xD;
                  Individuals who test positive for hepatitis B core antibody (anti-HBc) will&#xD;
                  require HBV deoxyribose nucleic acid (DNA) by quantitative polymerase chain&#xD;
                  reaction (PCR) for confirmation of active disease&#xD;
&#xD;
               -  Individuals who test positive for HCV antibody. These individuals will require&#xD;
                  HCV ribose nucleic acid (RNA) quantitative PCR for confirmation of active disease&#xD;
&#xD;
               -  Individuals who test positive for HIV antibody&#xD;
&#xD;
               -  Individuals not currently receiving antiviral therapy and who have an&#xD;
                  undetectable viral load in the prior 3 months may be eligible for the study.&#xD;
&#xD;
        Note: Other protocol defined Inclusion/Exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilead Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gilead Clinical Study Information Center</last_name>
    <phone>1-833-445-3230 (GILEAD-0)</phone>
    <email>GileadClinicalTrials@gilead.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>USC/ Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UC Irvine Health</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tulane Medical center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine - Siteman Cancer Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center - OU Health Stephenson Cancer Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University, Sidney Kimmel Cancer Center, Clinical Research Organization</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Francis Cancer Center</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Prisma Health Cancer Institute</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Alfred</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital, The Chinese University of Hong Kong</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Hong Kong</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.gileadclinicaltrials.com/study/?id=GS-US-546-5857</url>
    <description>Gilead Clinical Trials Website</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>February 23, 2021</study_first_submitted>
  <study_first_submitted_qc>March 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2021</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Azacitidine</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
    <mesh_term>Venetoclax</mesh_term>
    <mesh_term>Idarubicin</mesh_term>
    <mesh_term>Magrolimab</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

